Close Menu

multiplex assays

The company's DETECTR disease detection platform will be used to help develop the technology and optimize the CRISPR enzymes used in the point-of-care device.

The Germany-based company is developing Molecular Cartography, a technology that offers multiplexed analysis of gene expression in tissues.

The revenue increase was driven by significant growth in the conglomerate's life sciences segment.

The funding will help the San Francisco-based firm apply low-depth NGS as it builds diagnostic tests to aid therapy selection in more diverse populations.

The deal enables Genosity to add Olink's proteomics technology with next-generation sequencing readout to its repertoire of services.

The test runs on multiple GeneXpert systems and tests nasopharyngeal and nasal swabs or nasal wash/aspirate specimens.

French startup SeqOne has adapted its sequencing data-analysis platform to support a new method for high-throughput processing of coronavirus tests in its home country.

The assay detects 10 STIs and is performed on the molecular point-of-care Vivalytic platform, which was codeveloped by German company Bosch.

All three methods build on the use of methyltransferases to mark accessible regions of the genome, using nanopore sequencing to detect the modifications.

The test detects 20 common viruses and bacteria that cause upper respiratory infections using the firm's high-throughput, automated MDx-3000 instrument.

Pages

Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.

According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.

In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.